Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators.

N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.

PMID:
29562145
2.

Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.

Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC, Mainwaring PN, Hammers HJ, Lee JL, Roth BJ, Marteau F, Williams P, Baer J, Mangeshkar M, Scheffold C, Hutson TE, Pal S, Motzer RJ, Choueiri TK.

J Clin Oncol. 2018 Mar 10;36(8):757-764. doi: 10.1200/JCO.2017.75.2170. Epub 2018 Jan 29.

PMID:
29377755
3.

Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71].

Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ; CheckMate 025 investigators.

Eur Urol. 2018 Apr;73(4):e116-e118. doi: 10.1016/j.eururo.2017.12.016. Epub 2018 Jan 3. No abstract available.

PMID:
29306512
4.

Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870).

Pili R, Quinn DI, Hammers HJ, Monk P, George S, Dorff TB, Olencki T, Shen L, Orillion A, Lamonica D, Fragomeni RS, Szabo Z, Hutson A, Groman A, Perkins SM, Piekarz R, Carducci MA.

Clin Cancer Res. 2017 Dec 1;23(23):7199-7208. doi: 10.1158/1078-0432.CCR-17-1178. Epub 2017 Sep 22.

PMID:
28939740
5.

The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas.

Ball MW, Gorin MA, Drake CG, Hammers HJ, Allaf ME.

Eur Urol Focus. 2017 Dec;3(6):584-589. doi: 10.1016/j.euf.2017.01.007. Epub 2017 Feb 8.

PMID:
28753846
6.

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, Voss MH, Sharma P, Pal SK, Razak ARA, Kollmannsberger C, Heng DYC, Spratlin J, McHenry MB, Amin A.

J Clin Oncol. 2017 Dec 1;35(34):3851-3858. doi: 10.1200/JCO.2016.72.1985. Epub 2017 Jul 5.

PMID:
28678668
7.

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade.

Naidoo J, Cappelli LC, Forde PM, Marrone KA, Lipson EJ, Hammers HJ, Sharfman WH, Le DT, Baer AN, Shah AA, Albayda J, Manno RL, Haque U, Gutierrez AK, Bingham CO 3rd, Brahmer JR.

Oncologist. 2017 Jun;22(6):627-630. doi: 10.1634/theoncologist.2016-0390. Epub 2017 Jun 2. No abstract available.

8.

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.

Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG, Harmenberg U, McDermott DF, Choueiri TK, Richardet M, Tomita Y, Ravaud A, Doan J, Zhao H, Hardy H, George S.

Eur Urol. 2017 Sep;72(3):368-376. doi: 10.1016/j.eururo.2017.03.037. Epub 2017 Apr 12.

PMID:
28410865
9.

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.

Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ; CheckMate 025 investigators.

Eur Urol. 2017 Dec;72(6):962-971. doi: 10.1016/j.eururo.2017.02.010. Epub 2017 Mar 3. Erratum in: Eur Urol. 2018 Jan 3;:.

PMID:
28262413
10.

PSMA-Targeted 18F-DCFPyL PET/CT Imaging of Clear Cell Renal Cell Carcinoma: Results from a Rapid Autopsy.

Gorin MA, Rowe SP, Hooper JE, Kates M, Hammers HJ, Szabo Z, Pomper MG, Allaf ME.

Eur Urol. 2017 Jan;71(1):145-146. doi: 10.1016/j.eururo.2016.06.019. Epub 2016 Jun 28. No abstract available.

11.

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ; METEOR investigators.

Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5.

PMID:
27279544
12.

Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.

George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM, Rini BI.

JAMA Oncol. 2016 Sep 1;2(9):1179-86. doi: 10.1001/jamaoncol.2016.0775.

13.

Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study.

Ball MW, Gorin MA, Guner G, Pierorazio PM, Netto G, Paller CJ, Hammers HJ, Diaz LA, Allaf ME.

Clin Genitourin Cancer. 2016 Oct;14(5):e515-e520. doi: 10.1016/j.clgc.2016.03.019. Epub 2016 Mar 24. No abstract available.

14.

Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.

Nadal R, Amin A, Geynisman DM, Voss MH, Weinstock M, Doyle J, Zhang Z, Viudez A, Plimack ER, McDermott DF, Motzer R, Rini B, Hammers HJ.

Ann Oncol. 2016 Jul;27(7):1304-11. doi: 10.1093/annonc/mdw160. Epub 2016 Apr 7.

PMID:
27059553
15.

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators.

N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.

16.

Detection of 18F-FDG PET/CT Occult Lesions With 18F-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma.

Rowe SP, Gorin MA, Hammers HJ, Pomper MG, Allaf ME, Javadi MS.

Clin Nucl Med. 2016 Jan;41(1):83-5. doi: 10.1097/RLU.0000000000000995.

17.

Antagonists of PD-1 and PD-L1 in Cancer Treatment.

Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL.

Semin Oncol. 2015 Aug;42(4):587-600. doi: 10.1053/j.seminoncol.2015.05.013. Epub 2015 Jun 10. Review.

18.

Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.

Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, Cho SY, Pomper MG, Allaf ME.

Ann Nucl Med. 2015 Dec;29(10):877-82. doi: 10.1007/s12149-015-1017-z. Epub 2015 Aug 19.

19.

A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.

Paller CJ, Rudek MA, Zhou XC, Wagner WD, Hudson TS, Anders N, Hammers HJ, Dowling D, King S, Antonarakis ES, Drake CG, Eisenberger MA, Denmeade SR, Rosner GL, Carducci MA.

Prostate. 2015 Oct;75(14):1518-25. doi: 10.1002/pros.23024. Epub 2015 May 27.

20.

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, Brahmer JR, Carvajal RD, Hammers HJ, Puzanov I, Hodi FS, Kluger HM, Topalian SL, Pardoll DM, Wigginton JM, Kollia GD, Gupta A, McDonald D, Sankar V, Sosman JA, Atkins MB.

J Clin Oncol. 2015 Jun 20;33(18):2013-20. doi: 10.1200/JCO.2014.58.1041. Epub 2015 Mar 30.

21.

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ.

J Clin Oncol. 2015 May 1;33(13):1430-7. doi: 10.1200/JCO.2014.59.0703. Epub 2014 Dec 1.

22.

Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.

Hussain M, Corn PG, Michaelson MD, Hammers HJ, Alumkal JJ, Ryan CJ, Bruce JY, Moran S, Lee SY, Lin HM, George DJ; Prostate Cancer Clinical Trials Consortium, a program of the Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation.

Clin Cancer Res. 2014 Aug 15;20(16):4218-27. doi: 10.1158/1078-0432.CCR-14-0356. Epub 2014 Jun 25.

23.

Renal cell carcinoma presenting with brain metastasis from a 1.6 cm primary tumor.

Chalfin HJ, Gurda GT, Hammers HJ, Netto GJ, Bivalacqua TJ.

Can J Urol. 2013 Oct;20(5):6965-7.

PMID:
24128841
24.

Screening assay for blood vessel maturation inhibitors.

Fu C, van der Zwan A, Gerber S, Van Den Berg S, No E, Wang WC, Sheibani N, Carducci MA, Kachhap S, Hammers HJ.

Biochem Biophys Res Commun. 2013 Aug 23;438(2):364-9. doi: 10.1016/j.bbrc.2013.07.077. Epub 2013 Jul 25.

25.

Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.

Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E, Pradilla G, Ford E, Wong J, Hammers HJ, Mathios D, Tyler B, Brem H, Tran PT, Pardoll D, Drake CG, Lim M.

Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):343-9. doi: 10.1016/j.ijrobp.2012.12.025. Epub 2013 Feb 22.

26.

Denosumab for the treatment of bisphosphonate-refractory hypercalcemia.

Boikos SA, Hammers HJ.

J Clin Oncol. 2012 Oct 10;30(29):e299. doi: 10.1200/JCO.2012.41.7923. Epub 2012 Sep 4. No abstract available.

PMID:
22949145
27.

Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas.

Chaux A, Schultz L, Albadine R, Hicks J, Kim JJ, Allaf ME, Carducci MA, Rodriguez R, Hammers HJ, Argani P, Reuter VE, Netto GJ.

Hum Pathol. 2012 Dec;43(12):2129-37. doi: 10.1016/j.humpath.2012.01.009. Epub 2012 Apr 26.

28.

Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.

Schultz L, Chaux A, Albadine R, Hicks J, Kim JJ, De Marzo AM, Allaf ME, Carducci MA, Rodriguez R, Hammers HJ, Argani P, Reuter VE, Netto GJ.

Am J Surg Pathol. 2011 Oct;35(10):1549-56. doi: 10.1097/PAS.0b013e31822895e5.

29.

Development of a research agenda for percutaneous renal tumor ablation: proceedings from a multidisciplinary research consensus panel.

Georgiades CS, Rodriguez R, Littrup PJ, Frangakis CE, Leveille R, Ahrar K, Atwell TD, Cadeddu J, Trimmer C, Durack JC, Hammers HJ, Meng MV, Raman S, Solomon SB, Zagoria RJ, McLennan G, Laberge JM, Gervais DA, Kee ST.

J Vasc Interv Radiol. 2010 Dec;21(12):1807-16. doi: 10.1016/j.jvir.2010.10.002. No abstract available.

PMID:
21111363
30.

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.

Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G, Pili R.

Mol Cancer Ther. 2010 Jun;9(6):1525-35. doi: 10.1158/1535-7163.MCT-09-1106. Epub 2010 May 25.

31.

Ultraviolet-induced detection of halogenated pyrimidines (UVID).

Hammers HJ, Schlenke P.

Curr Protoc Cytom. 2001 May;Chapter 7:Unit 7.15. doi: 10.1002/0471142956.cy0715s16.

PMID:
18770727
32.

Withaferin A is a potent inhibitor of angiogenesis.

Mohan R, Hammers HJ, Bargagna-Mohan P, Zhan XH, Herbstritt CJ, Ruiz A, Zhang L, Hanson AD, Conner BP, Rougas J, Pribluda VS.

Angiogenesis. 2004;7(2):115-22.

PMID:
15516832
33.

Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity.

Hembrough TA, Ruiz JF, Swerdlow BM, Swartz GM, Hammers HJ, Zhang L, Plum SM, Williams MS, Strickland DK, Pribluda VS.

Blood. 2004 May 1;103(9):3374-80. Epub 2004 Jan 22.

34.

Individual variability in cyclosporin A sensitivity: the assessment of functional measures on CD28-mediated costimulation of human whole blood T lymphocytes.

Härtel C, Hammers HJ, Schlenke P, Fricke L, Schumacher N, Kirchner H, Müller-Steinhardt M.

J Interferon Cytokine Res. 2003 Feb;23(2):91-9.

PMID:
12744774
35.

Introduction of a novel proliferation assay for pharmacological studies allowing the combination of BrdU detection and phenotyping.

Hammers HJ, Saballus M, Sheikzadeh S, Schlenke P.

J Immunol Methods. 2002 Jun 1;264(1-2):89-93.

PMID:
12191513
36.

Improvement of the precision in CFU-GM and BFU-E counting by flow cytometry-based standardization of short-term culture assays.

Sheikhzadeh S, Hammers HJ, Hartwig D, Kirchner H, Schlenke P.

J Hematother Stem Cell Res. 2001 Dec;10(6):881-5.

PMID:
11798514
37.
38.

Differential expression of the B cell-restricted molecule CD22 on neonatal B lymphocytes depending upon antigen stimulation.

Viemann D, Schlenke P, Hammers HJ, Kirchner H, Kruse A.

Eur J Immunol. 2000 Feb;30(2):550-9.

39.

Evaluation of a flow cytometric method for simultaneous leukocyte phenotyping and quantification by fluorescent microspheres.

Schlenke P, Frohn C, Klüter H, Saballus M, Hammers HJ, Zajac SR, Kirchner H.

Cytometry. 1998 Nov 1;33(3):310-7.

PMID:
9822341
40.

Evaluation of a novel mononuclear cell isolation procedure for serological HLA typing.

Schlenke P, Klüter H, Müller-Steinhardt M, Hammers HJ, Borchert K, Bein G.

Clin Diagn Lab Immunol. 1998 Nov;5(6):808-13.

Supplemental Content

Loading ...
Support Center